ClinicalTrials.gg
CompletedNCT05417009VANSUpdated Jul 14, 2025Results posted

Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.

An interventional study of trans-cutaneous auricular sensory stimulation in Ischemic Stroke, Thrombotic Stroke and Autonomic Dysfunction, sponsored by Queen Mary University of London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2025-07-14.

Primary conditionThrombotic StrokeRegistry: Ischemic StrokeReclassifiedWhy we changed it
Registry
Ischemic Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Thrombotic Stroke
Why
  1. The study's listed conditions name Thrombotic Stroke, a narrower term within Ischemic Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Queen Mary University of London · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

Autonomic modulation by transcutaneous vagal nerve stimulation in acute ischaemic stroke requiring mechanical thrombectomy: a phase IIa, sham controlled randomised trial.

Read the detailed description

Loss of autonomic variability is strongly associated with adverse outcomes after ischaemic stroke. Removing blood clots from the brain by mechanical thrombectomy has revolutionised the management of stroke, but more than 50% of patients do not regain functional independence.(PMID:26898852) Blood pressure (BP) control is important, since low and high BP (BP variability) are strongly associated with poor patient outcomes after thrombectomy. (PMIDs:32961389;31964286) Autonomic dysfunction causes labile blood pressure. Intact autonomic function is required to control blood pressure and potentially improve recovery after stroke. Impairment of baroreflex autonomic function, due to reduced vagal activity is associated with extreme BP variability, leading to further brain injury and cardiovascular complications.(PMID:30371208) Reduced baroreflex control is related to poor patient outcomes after stroke, independent of absolute blood pressure.(PMID:19834010) Reversing baroreflex and vagal dysfunction is, therefore, widely held to have the potential to improve cardiovascular control and patient outcome in this context.(PMID:19834010)

Non-invasive peripheral neuromodulation restores autonomic control. Vagal nerve stimulation improves autonomic control and reverses baroreflex dysfunction (PMIDs:28949064) but this has previously required surgically implanted devices which are expensive and impractical in the context of acute stroke. Afferent Electronic have achieved the same effect as these implantable devices by non-invasive transcutaneous autonomic neuromodulation (TAN). We have used this simple, safe, hand-held, low-cost device to increase vagal activity and baroreflex sensitivity through non-invasive, painless stimulation of nerves located in the outer ear to control blood pressure.

Baroreflex sensitivity can be increased at the bedside by TAN for 30 minutes following acute trauma. If this can be replicated in thrombectomy patients, it will aid recovery and rehabilitation through five complementary mechanisms where it has been clinically demonstrated that increasing vagal nerve activity:

  1. Restore baroreflex sensitivity;
  2. Increase blood flow to ischaemic brain tissue through vagal activation.(PMID:27357059)
  3. Dampen cerebral/systemic inflammation.(PMID:26723020);
  4. Reduce atrial fibrillation and myocardial injury,(PMIDs:5744003,22739118) which are common after stroke, and independently predict cognitive decline and cardiovascular mortality
  5. Allows immediate commencement of vagal nerve stimulation, which has recently been shown to enhance upper-limb rehabilitation.(PMID:33894832) Our proof-of-concept data shows daily TAN reduces BP and BP variability lasting several months even in drug-resistant hypertensive patients. In this proof-of-concept randomised sham-controlled trial, we will examine whether early TAN on presentation for mechanical thrombectomy improves autonomic function in patients with acute ischaemic stroke by reducing blood pressure lability.
02

Conditions studied

  • Ischemic Stroke
  • Thrombotic Stroke
  • Autonomic Dysfunction
  • Autonomic Imbalance

Browse trials for

03

In context

Thrombotic Stroke Reclassified

21 studies on the registry are indexed under Thrombotic Stroke; 8 are open to participants now.

This study's enrollment of 36 is below the median of 85 across 13 interventional studies indexed under Thrombotic Stroke.

Browse Thrombotic Stroke studies →

Lead sponsor

Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.

Compared within Thrombotic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ischemic Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing mechanical thrombectomy for acute ischaemic stroke requiring general or sedation.
  • Established hypertensive and/or hypertensive on admission for mechanical thrombectomy [systolic BP >140mmHg; diastolic BP >80mmHg]

Exclusion criteria

Exclusion Criteria:

  • Current participation in a clinical trial of a treatment with a similar biological mechanism.
  • Previous enrolment into VANS trial.
  • Anatomical or other to trans-cutaneous auricular sensory stimulation
  • Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Stimulation

    Electrodes attached bliaterally to tragus nerve region of outer ear, with appropriate device settings to deliver current.

    Device: trans-cutaneous auricular sensory stimulation

  • Sham comparator
    Electrode attachment only.

    Electrodes attached bliaterally to tragus nerve region of outer ear, with device switched off \[blinded to operator\].

    Device: trans-cutaneous auricular sensory stimulation

Interventions

  • Devicetrans-cutaneous auricular sensory stimulation

    Transcutaneous auricular sensory stimulation

06

What researchers measure

Primary outcomes

  1. Blood Pressure Variability

    Coefficient of variation of systolic blood pressure

    Time frame: 0-24h after mechanical thrombectomy

Secondary outcomes

  1. Systolic Blood Pressure Variability.

    Systolic blood pressure standard deviation.

    Time frame: 0-24h after mechanical thrombectomy

  2. Diastolic Blood Pressure Variability

    coefficient of variation- diastolic blood pressure

    Time frame: 24h after admission for mechanical thrombectomy

07

Results

Posted Jul 14, 2025

Participant flow

Patients referred for urgent mechanical thrombectomy.

Participant flow — Overall Study
MilestoneStimulation - n=18Electrode Attachment Only - n=18
Started1818
Completed1818
Not completed00

Outcome measures

PrimaryBlood Pressure Variability

Coefficient of variation of systolic blood pressure

Time frame:
0-24h after mechanical thrombectomy
Reported as:
Mean · coefficient of variation
Blood Pressure Variability
coefficient of variationStimulationElectrode Attachment Only.
Blood Pressure Variability0.106 ± 0.0290.107 ± 0.027
SecondarySystolic Blood Pressure Variability.

Systolic blood pressure standard deviation.

Time frame:
0-24h after mechanical thrombectomy
Reported as:
Mean · mmHg
Systolic Blood Pressure Variability.
mmHgStimulation - n=18Electrode Attachment Only - n=18
Systolic Blood Pressure Variability.14 ± 514 ± 4
SecondaryDiastolic Blood Pressure Variability

coefficient of variation- diastolic blood pressure

Time frame:
24h after admission for mechanical thrombectomy
Reported as:
Mean · coefficient of variation
Diastolic Blood Pressure Variability
coefficient of variationStimulationElectrode Attachment Only.
Diastolic Blood Pressure Variability0.136 ± 0.050.127 ± 0.04

Adverse events

Collected over From randomisation until 7 days after thrombectomy. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stimulation - n=180/18 (0%)0/18 (0%)2/18 (11.1%)
Electrode Attachment Only - n=182/18 (11.1%)0/18 (0%)0/18 (0%)
Most frequent other events
Most frequent other events
EventStimulation - n=18Electrode Attachment Only - n=18
Skin irritationSkin and subcutaneous tissue disorders1/180/18
Anaesthetic complicationRespiratory, thoracic and mediastinal disorders1/180/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Stimulation - n=18Electrode Attachment Only - n=18Total
<=18 years000
Between 18 and 65 years7512
>=65 years111324
Age, Continuous
Age, Continuous(years)Stimulation - n=18Electrode Attachment Only - n=18Total
Mean69 ± 1369 ± 1569 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Stimulation - n=18Electrode Attachment Only - n=18Total
Female13922
Male5914
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stimulation - n=18Electrode Attachment Only - n=18Total
Non-white8311
Other101525
Region of Enrollment
Region of Enrollment(participants)Stimulation - n=18Electrode Attachment Only - n=18Total
United Kingdom181836
08

Study locations

1 site
  • William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square
    London, EC1M 6BQ, United Kingdom
09

References and documents

Publications

  • Ackland GL, Crane D, Ahuja S, Patel A, Martin T, Joseph M, Ottley O, Hameed R, Dias P, Begum S, Schroth J, Hewson R, Del Arroyo AG, Abbott TEF, Bhogal P. Transauricular Vagus Nerve Stimulation in Acute Ischaemic Stroke Requiring Mechanical Thrombectomy: Sham-Controlled, Randomised Device Trial. Transl Stroke Res. 2025 Dec 27;17(1):10. doi: 10.1007/s12975-025-01404-7. PubMed 41455014 ↗
  • Ackland GL, Martin T, Joseph M, Dias P, Hameed R, Gutierrez Del Arroyo A, Hewson R, Abbott TEF, Spooner O, Bhogal P. Transauricular nerve stimulation in acute ischaemic stroke requiring mechanical thrombectomy: Protocol for a phase 2A, proof-of-concept, sham-controlled randomised trial. PLoS One. 2023 Dec 22;18(12):e0289719. doi: 10.1371/journal.pone.0289719. eCollection 2023. PubMed 38134136 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Researchers who provide a methodologically sound proposal approved by an independent review committee intermediary using deidentified data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: No end date.

Access criteria: To achieve aims in approved proposal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jul 2023, 2 months.

Results were first posted in Jul 2025, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 14, 2022
StartActual
Apr 26, 2023
Primary completionActual
Jul 21, 2023
CompletionActual
Jul 21, 2023
Results first posted
Jul 14, 2025
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05417009
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Apr 26, 2023
Primary completion
Jul 21, 2023
Completion
Jul 21, 2023
Results posted
Jul 14, 2025
Last update
Jul 14, 2025

Study contacts

Gareth L Ackland, PhD FRCA
principal investigator · William Harvey Research Institute, Queen Mary University of London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion